Publication date: Oct 05, 2019
With this understanding and the rise of immunotherapy and genomic sequencing, a vast chunk of current cancer research now focuses on finding biomarkers that can predict disease response to certain drugs and guide therapy protocols.
Dr Banna and his colleagues recently published a paper exploring the -promise of digital biopsy” for predicting immunotherapy outcomes based on radiomics and pathomics. 1 Although molecular determinants such as PD-1 or PD-L1 expression, and tumor mutational burden (TMB), are already used in clinical practice, these -fail in consistency, applicability, or reliability to precisely identify the responding patients mainly because of their spatial intratumoral heterogeneity,” they wrote.
- Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
- The potential use of big data in oncology.
- Translational genomics and precision medicine: Moving from the lab to the clinic
- In AI We Trust? The Future of Genomic Medicine